152 related articles for article (PubMed ID: 36627869)
1. Price and reimbursement for orphan medicines and managed entry agreements: does Italy need a framework?
Jommi C; Addis A; Martini N; Nicod E; Pani M; Scopinaro A; Vogler S
Glob Reg Health Technol Assess; 2021; 8():114-119. PubMed ID: 36627869
[TBL] [Abstract][Full Text] [Related]
2. Determinants of price negotiations for new drugs. The experience of the Italian Medicines Agency.
Villa F; Tutone M; Altamura G; Antignani S; Cangini A; Fortino I; Melazzini M; Trotta F; Tafuri G; Jommi C
Health Policy; 2019 Jun; 123(6):595-600. PubMed ID: 31097207
[TBL] [Abstract][Full Text] [Related]
3. Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel.
Facey KM; Espin J; Kent E; Link A; Nicod E; O'Leary A; Xoxi E; van de Vijver I; Zaremba A; Benisheva T; Vagoras A; Upadhyaya S
Pharmacoeconomics; 2021 Sep; 39(9):1021-1044. PubMed ID: 34231135
[TBL] [Abstract][Full Text] [Related]
4. Introduction of managed entry agreements in Korea: Problem, policy, and politics.
Kim H; Godman B; Kwon HY; Hong SH
Front Pharmacol; 2023; 14():999220. PubMed ID: 37124231
[No Abstract] [Full Text] [Related]
5. The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal.
Hettle R; Corbett M; Hinde S; Hodgson R; Jones-Diette J; Woolacott N; Palmer S
Health Technol Assess; 2017 Feb; 21(7):1-204. PubMed ID: 28244858
[TBL] [Abstract][Full Text] [Related]
6. [Early access programs and managed entry agreements for medicines in Italy: results of a Focus Group (Early Access Programs and Managed Entry Agreement).].
Jommi C; Armeni P; Costa F; Alberti C; Bandello F; Bordonaro R; Caprodossi A; Di Maio M; Gaudioso A; Giuliani G; Langella R; Marata AM; Patarnello F; Pinto C; Rasi G; Villa F
Recenti Prog Med; 2021 Nov; 112(11):749-756. PubMed ID: 34782810
[TBL] [Abstract][Full Text] [Related]
7. CHARACTERISTICS OF MANAGED ENTRY AGREEMENTS IN AUSTRALIA.
Robinson MF; Mihalopoulos C; Merlin T; Roughead E
Int J Technol Assess Health Care; 2018 Jan; 34(1):46-55. PubMed ID: 29277174
[TBL] [Abstract][Full Text] [Related]
8. [Establishing the value of new drugs in Italy.].
Villa F; Jommi C; Altamura G; Antignani S; Cangini A; Fortino I; Melazzini M; Trotta F; Tafuri G
Recenti Prog Med; 2020 Feb; 111(2):65-69. PubMed ID: 32089554
[TBL] [Abstract][Full Text] [Related]
9. Dealing with uncertainty and high prices of new medicines: a comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden.
Ferrario A; Kanavos P
Soc Sci Med; 2015 Jan; 124():39-47. PubMed ID: 25461860
[TBL] [Abstract][Full Text] [Related]
10. Orphan Drug Prices and Epidemiology of Rare Diseases: A Cross-Sectional Study in Italy in the Years 2014-2019.
Villa F; Di Filippo A; Pierantozzi A; Genazzani A; Addis A; Trifirò G; Cangini A; Tafuri G; Settesoldi D; Trotta F
Front Med (Lausanne); 2022; 9():820757. PubMed ID: 35252257
[TBL] [Abstract][Full Text] [Related]
11. Managed Entry Agreements: Policy Analysis From the European Perspective.
Dabbous M; Chachoua L; Caban A; Toumi M
Value Health; 2020 Apr; 23(4):425-433. PubMed ID: 32327159
[TBL] [Abstract][Full Text] [Related]
12. Impact of Managed Entry Agreements on availability of and timely access to medicines: an ex-post evaluation of agreements implemented for oncology therapies in four countries.
Efthymiadou O; Kanavos P
BMC Health Serv Res; 2022 Aug; 22(1):1066. PubMed ID: 35987627
[TBL] [Abstract][Full Text] [Related]
13. Managed entry agreements for pharmaceuticals in Australia.
Vitry A; Roughead E
Health Policy; 2014 Sep; 117(3):345-52. PubMed ID: 24957419
[TBL] [Abstract][Full Text] [Related]
14. Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries.
Morel T; Arickx F; Befrits G; Siviero P; van der Meijden C; Xoxi E; Simoens S
Orphanet J Rare Dis; 2013 Dec; 8():198. PubMed ID: 24365263
[TBL] [Abstract][Full Text] [Related]
15. The Evolution of AIFA Registries to Support Managed Entry Agreements for Orphan Medicinal Products in Italy.
Xoxi E; Facey KM; Cicchetti A
Front Pharmacol; 2021; 12():699466. PubMed ID: 34456724
[TBL] [Abstract][Full Text] [Related]
16. Access and pricing of medicines for patients with rare diseases in the European Union: an industry perspective.
Tafuri G; Bracco A; Grueger J
Expert Rev Pharmacoecon Outcomes Res; 2022 Apr; 22(3):381-389. PubMed ID: 34930086
[TBL] [Abstract][Full Text] [Related]
17. A Proposal for Value-Based Managed Entry Agreements in an Environment of Technological Change and Economic Challenge for Publicly Funded Healthcare Systems.
Xoxi E; Rumi F; Kanavos P; Dauben HP; Gutierrez-Ibarluzea I; Wong O; Rasi G; Cicchetti A
Front Med Technol; 2022; 4():888404. PubMed ID: 35782579
[TBL] [Abstract][Full Text] [Related]
18. Orphan drugs' clinical uncertainty and prices: Addressing allocative and technical inefficiencies in orphan drug reimbursement.
Eichler HG; Kossmeier M; Zeitlinger M; Schwarzer-Daum B
Front Pharmacol; 2023; 14():1074512. PubMed ID: 36778019
[TBL] [Abstract][Full Text] [Related]
19. Reimbursed Price of Orphan Drugs: Current Strategies and Potential Improvements.
Mincarone P; Leo CG; Sabina S; Sarriá-Santamera A; Taruscio D; Serrano-Aguilar PG; Kanavos P
Public Health Genomics; 2017; 20(1):1-8. PubMed ID: 28359063
[TBL] [Abstract][Full Text] [Related]
20. Managed Entry Agreements for Pharmaceutical Products in Middle East and North African Countries: Payer and Manufacturer Experience and Outlook.
Maskineh C; Nasser SC
Value Health Reg Issues; 2018 Sep; 16():33-38. PubMed ID: 29936067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
